Last10K.com

Abbott Laboratories (ABT) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Abbott Laboratories

CIK: 1800 Ticker: ABT

Exhibit 99.1

 

News Release

 

Abbott Reports Fourth-Quarter 2015 Results

 

·                 FOURTH-QUARTER ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.62; GAAP EPS FROM CONTINUING OPERATIONS OF $0.46

·                 FULL-YEAR OPERATIONAL SALES GROWTH OF 9.1 PERCENT, INCLUDING 17.1 PERCENT GROWTH IN EMERGING MARKETS; FULL-YEAR REPORTED SALES GROWTH OF 0.8 PERCENT

·                 FULL-YEAR ADJUSTED EPS GROWTH FROM CONTINUING OPERATIONS OF 8.6 PERCENT AND GAAP EPS GROWTH FROM CONTINUING OPERATIONS OF 53.6 PERCENT

·                 SIGNIFICANT EXPANSION OF FULL-YEAR GROSS AND OPERATING MARGIN RATIOS

·                 ISSUES EARNINGS OUTLOOK FOR 2016, REFLECTING DOUBLE-DIGIT UNDERLYING GROWTH OFFSET BY FOREIGN EXCHANGE AND A SIGNIFICANTLY LOWER CONTRIBUTION FROM VENEZUELAN OPERATIONS

 

ABBOTT PARK, Ill., Jan. 28, 2016 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2015.

 

·                  Adjusted diluted EPS from continuing operations, which excludes specified items, was $0.62 in the fourth quarter and $2.15 for the full year, at the midpoint of Abbott’s previous guidance range and reflecting 8.6 percent growth for the full year. Reported diluted EPS from continuing operations under GAAP was $0.46 in the fourth quarter and $1.72 for the full year.

 

·                  Fourth-quarter worldwide sales of $5.2 billion increased 4.9 percent on an operational basis and decreased 3.1 percent on a reported basis.

 

·                  Full-year sales increased 9.1 percent on an operational basis and 0.8 percent on a reported basis. Full-year sales in emerging markets increased double digits excluding the impact of 2014 acquisitions and foreign exchange.

 

·                  For the full year 2015, Abbott expanded its adjusted gross and operating margin ratios by 260 and 90 basis points over the prior year, respectively. The gross and operating margin ratios under GAAP improved by 250 and 120 basis points over the prior year, respectively.

 

·                  Abbott issues full-year 2016 adjusted EPS guidance range of $2.10 to $2.20. Projected full-year 2016 EPS under GAAP is $1.55 to $1.65. Abbott’s 2016 forecast assumes a significantly lower contribution from Venezuelan operations as a result of challenging market conditions in that country. Excluding the impact of foreign exchange and Venezuela, the midpoint of Abbott’s 2016 adjusted EPS guidance range would reflect strong double-digit growth.

 

“In 2015, we achieved top-tier sales and earnings growth despite a challenging currency environment,” said Miles D. White, chairman and chief executive officer, Abbott. “Our underlying performance continues to be strong.”

 


The following information was filed by Abbott Laboratories (ABT) on Thursday, January 28, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Abbott Laboratories's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abbott Laboratories.

Continue

Assess how Abbott Laboratories's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abbott Laboratories's Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheet
Consolidated Balance Sheet (parenthetical)
Consolidated Statement Of Cash Flows
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (parenthetical)
Consolidated Statement Of Earnings
Consolidated Statement Of Shareholders' Investment
Consolidated Statement Of Shareholders' Investment (parenthetical)
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (details)
Accumulated Other Comprehensive Income (tables)
Business Acquisitions
Business Acquisitions (details)
Business Acquisitions (tables)
Debt And Lines Of Credit
Debt And Lines Of Credit (details)
Debt And Lines Of Credit (tables)
Discontinued Operations
Discontinued Operations (details 2)
Discontinued Operations (details)
Discontinued Operations (tables)
Financial Instruments, Derivatives And Fair Value Measures
Financial Instruments, Derivatives And Fair Value Measures (details 2)
Financial Instruments, Derivatives And Fair Value Measures (details 3)
Financial Instruments, Derivatives And Fair Value Measures (details 4)
Financial Instruments, Derivatives And Fair Value Measures (details)
Financial Instruments, Derivatives And Fair Value Measures (tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (details 2)
Goodwill And Intangible Assets (details)
Incentive Stock Programs
Incentive Stock Programs (details)
Incentive Stock Programs (tables)
Litigation And Environmental Matters
Litigation And Environmental Matters (details)
Post-employment Benefits
Post-employment Benefits (details 2)
Post-employment Benefits (details 3)
Post-employment Benefits (details)
Post-employment Benefits (tables)
Quarterly Results (unaudited)
Quarterly Results (unaudited) (details)
Quarterly Results (unaudited) (tables)
Restructuring Plans
Restructuring Plans (details)
Restructuring Plans (tables)
Schedule Ii Valuation And Qualifying Accounts
Schedule Ii Valuation And Qualifying Accounts (details)
Segment And Geographic Area Information (details 3)
Segment And Geographical Area Information
Segment And Geographical Area Information (details 2)
Segment And Geographical Area Information (details)
Segment Information And Geographical Area Information (tables)
Separation Of Abbvie Inc.
Separation Of Abbvie Inc. (details)
Subsequent Event
Subsequent Event (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details 2)
Summary Of Significant Accounting Policies (details 3)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Income Taxes (details)
Supplemental Financial Information
Supplemental Financial Information (details)
Supplemental Financial Information (tables)
Taxes On Earnings From Continuing Operations
Taxes On Earnings From Continuing Operations (details 2)
Taxes On Earnings From Continuing Operations (details)
Taxes On Earnings From Continuing Operations (tables)
Ticker: ABT
CIK: 1800
Form Type: 10-K Annual Report
Accession Number: 0001047469-16-010246
Submitted to the SEC: Fri Feb 19 2016 3:48:41 PM EST
Accepted by the SEC: Fri Feb 19 2016
Period: Thursday, December 31, 2015
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/abt/0001047469-16-010246.htm